Targeting erbB Pathways in Breast Cancer: Dual Kinase Inhibition for Brain Metastasis and Prevention of p185HER2/Neu Tumor Development
ER121 is a non-toxic small-molecule erbB kinase inhibitor and holds promise as an oral and systemic therapeutic agent for treating progressive erbB-driven tumors in therapeutic settings. Moreover, ER121 shows potential as a preventive therapy in neoadjuvant settings for erbB2-associated tumors and when administered systemically can dramatically limit erbB2 brain metastases in animal models.
Authors
- Wei Qian
- Makoto Katsumata (ORCID: https://orcid.org/0000-0003-4751-2145)
- Payal Grover
- Arabinda Samanta (ORCID: https://orcid.org/0009-0007-6252-5282)
- Peeyush N. Goel
- George Sgouros (ORCID: https://orcid.org/0000-0002-4553-2866)
- Jenny Chia-Chen Chang (ORCID: https://orcid.org/0009-0003-5086-5918)
- Sunil Mathur (ORCID: https://orcid.org/0000-0001-7258-1594)
- Mei Ji (ORCID: https://orcid.org/0000-0001-8137-1441)
- Mark I. Greene (ORCID: https://orcid.org/0000-0001-6589-9668)
Institutions
- Cedars-Sinai Medical Center (US)
- Children's Hospital of Philadelphia (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Methodist Hospital (US)
- Methodist Hospital (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Breast Cancer Targets and Therapy
- Published
- 2024-10-01
- DOI
- https://doi.org/10.2147/bctt.s490904
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Breast Cancer Research Foundation
- National Institutes of Health